By simultaneously considering both of CA19-9 and CEA levels, we evaluated the mutation frequencies from the 22 patients with high CA19-9 (≥ 25) and CEA (≥ 5) levels in comparison with the other 150 patients to characterize the mutations from patients with more advanced colorectal cancer. The gene discussed is CEACAM5; the disease is colorectal cancer.